MARKET WIRECNBC • 1h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why GRDN Stock advanced +0.30% Today — RQD Quant Desk Flash
$40.45 +0.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
Guardian Pharmacy Services Inc. (Class A) (GRDN) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $2.56B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B+
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRDN)Realized 20D OHLCV Swing Band: ±7.4%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GRDN Stock advanced +0.30% Today — RQD Quant Desk Flash
Guardian Pharmacy Services Inc. (Class A) (GRDN) advanced +0.30% to $40.45, trading at 64% of its 52-week range ($26.34 – $48.33). High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 64% of its 52-week range ($26.34 – $48.33) with RSI-14 at 50.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.4% around $40.45 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 20.2% gross margin and $100.3M annual free cash flow.
Live GRDN Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 3h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 6h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 6h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (GRDN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.03%🛡️ HOLDING TREND SUPPORT
2026-10-30O $40.98H $41.37L $40.26C $40.45VOL 319.0K
RES: $49.88SUP: $39.08SMA50: $41.05SMA200: $38.08
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
37.5%/yr Implied 5Y Growth
vs. +17.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GRDN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GRDN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRDN)
Consumer Staples Rank #4 of 146
⚔️ CVS vs GRDN Full Matrix →
1. Head-to-Head Consumer Staples Peer Comparison (GRDN vs. CVS, YI, PETS, RDGT)
Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)Across 146 tracked Consumer Staples securities in the Roarable RQD universe, Guardian Pharmacy Services Inc. (Class A) (GRDN) ranks #4 by composite RQD confidence (77/100, grade B+) and #53 by equity capitalization ($2.56B). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GRDN
ACTIVE
Guardian Pharmacy Services Inc. (Class A) | B+ | 77/100 | 52.1x | 20.2% | 37.7% | +0.30% | $2.56B | Benchmark Subject |
| CVS CVS Health Corporation | C- | 61/100 | 65.3x | 45.0% | 2.6% | +0.42% | $115.53B | /cvs-vs-grdn → |
| YI 111 Inc. | D- | 42/100 | — | 5.8% | -20.5% | +0.34% | $26.2M | /yi-vs-grdn → |
| PETS PetMed Express Inc. | E | 26/100 | — | 28.1% | -35.0% | -0.84% | $25.6M | /pets-vs-grdn → |
| RDGT Ridgetech Inc. | D- | 43/100 | — | 3.6% | — | -2.45% | $3.0M | /rdgt-vs-grdn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802255In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardian Pharmacy Services Inc. (Class A) (GRDN) reported GAAP revenue of $1.45B (+17.9% vs. FY2024 revenue of $1.23B ) , GAAP net income of $49.2M, operating cash flow of $100.3M, and free cash flow of $100.3M (+73.0% YoY). On the balance sheet, GRDN closed FY2025 with $412.7M in total assets against $0 in total debt (Altman Z-Score: 12.39, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.45B | $49.2M | $100.3M | $100.3M | $412.7M | — |
| FY2024 (FY) | 2024-12-31 | $1.23B | -$110.0M | $58.0M | $58.0M | $320.8M | — |
3. GRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Guardian Pharmacy Services Inc. (Class A) (NYSE: GRDN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $40.45 (+0.30% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 146 tracked Consumer Staples issuers, GRDN ranks #4 in composite RQD confidence.
How does GRDN compare to CVS and YI in the Consumer Staples sector?
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), GRDN carries a Roarable B+ (77/100 RQD), trailing P/E of 52.1x, gross margin of 20.2%, and ROIC of 37.7%. By comparison, CVS (CVS Health Corporation) holds a C- grade (61/100 RQD, P/E 65.3x, ROIC 2.6%, cap $115.53B) and YI (111 Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GRDN?
Per GRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802255), Guardian Pharmacy Services Inc. (Class A) generated $1.45B in revenue (+17.9% YoY), $49.2M in net income, and $100.3M in free cash flow against $412.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GRDN trading relative to its 50-day, 200-day, and 52-week technical levels?
GRDN last traded at $40.45 (+0.30% on volume of 208,031 shares), positioning the stock -1.46% below its 50-day simple moving average ($41.05) and +6.22% above its 200-day simple moving average ($38.08). Across its 52-week range of $26.34 to $48.33, GRDN sits at the 64.2% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($37.46 to $43.44).
GRDN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GRDN stock moving today?
Why GRDN Stock advanced +0.30% Today — RQD Quant Desk Flash. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support.